2020
Safety of Revascularization Deferral of Left Main Stenosis Based on Instantaneous Wave-Free Ratio Evaluation
Warisawa T, Cook CM, Rajkumar C, Howard JP, Seligman H, Ahmad Y, El Hajj S, Doi S, Nakajima A, Nakayama M, Goto S, Vera-Urquiza R, Sato T, Kikuta Y, Kawase Y, Nishina H, Petraco R, Al-Lamee R, Nijjer S, Sen S, Nakamura S, Lerman A, Matsuo H, Francis DP, Akashi YJ, Escaned J, Davies JE. Safety of Revascularization Deferral of Left Main Stenosis Based on Instantaneous Wave-Free Ratio Evaluation. JACC Cardiovascular Interventions 2020, 13: 1655-1664. PMID: 32417088, DOI: 10.1016/j.jcin.2020.02.035.Peer-Reviewed Original ResearchMeSH KeywordsAgedClinical Decision-MakingCoronary Artery BypassCoronary Artery DiseaseCoronary StenosisEuropeFemaleFractional Flow Reserve, MyocardialHumansJapanMaleMiddle AgedPercutaneous Coronary InterventionPredictive Value of TestsProspective StudiesRegistriesRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTime-to-TreatmentTreatment OutcomeUnited StatesConceptsInstantaneous wave-free ratioNonfatal myocardial infarctionPrimary endpointLM stenosisCause deathLesion revascularizationSecondary endpointsCardiac deathMyocardial infarctionIschemia-driven target lesion revascularizationSimilar long-term outcomesStable coronary artery diseaseMain coronary artery stenosisLong-term clinical outcomesSafety of deferralMulticenter observational studyTarget lesion revascularizationLeft main stenosisCoronary artery diseaseLong-term outcomesCoronary artery stenosisDeferred groupLM revascularizationMedian followRevascularization deferral
2019
Determining the Predominant Lesion in Patients With Severe Aortic Stenosis and Coronary Stenoses
Ahmad Y, Vendrik J, Eftekhari A, Howard JP, Cook C, Rajkumar C, Malik I, Mikhail G, Ruparelia N, Hadjiloizou N, Nijjer S, Al-Lamee R, Petraco R, Warisawa T, Wijntjens GWM, Koch KT, van de Hoef T, de Waard G, Echavarria-Pinto M, Frame A, Sutaria N, Kanaganayagam G, Ariff B, Anderson J, Chukwuemeka A, Fertleman M, Koul S, Iglesias JF, Francis D, Mayet J, Serruys P, Davies J, Escaned J, van Royen N, Götberg M, Terkelsen C, Christiansen E, Piek JJ, Baan J, Sen S. Determining the Predominant Lesion in Patients With Severe Aortic Stenosis and Coronary Stenoses. Circulation Cardiovascular Interventions 2019, 12: e008263-e008263. PMID: 31752515, PMCID: PMC6924937, DOI: 10.1161/circinterventions.119.008263.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve StenosisBlood Flow VelocityCardiac CatheterizationCoronary Artery DiseaseCoronary CirculationCoronary StenosisCoronary VesselsEuropeFemaleHemodynamicsHumansMaleMicrocirculationPercutaneous Coronary InterventionPredictive Value of TestsRecovery of FunctionSeverity of Illness IndexTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsTranscatheter aortic valve implantationSevere aortic stenosisPercutaneous coronary interventionAortic stenosisCoronary artery diseaseCoronary stenosisIntermediate coronary stenosisCoronary diseaseCoronary interventionArtery diseaseCoronary microcirculationWave-free periodInstantaneous wave-free ratio valueConcomitant coronary artery diseaseConcomitant coronary diseaseAortic valve implantationInstantaneous wave-free ratioPhysiology-guided revascularizationExertional symptomsPost-TAVIHemodynamic improvementHemodynamic benefitsValve implantationCoronary lesionsMicrovascular resistance
2013
Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation
Myat A, Ahmad Y, Haldar S, Tantry US, Redwood SR, Gurbel PA, Lip GY. Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. Expert Review Of Cardiovascular Therapy 2013, 11: 1029-1049. PMID: 23984927, DOI: 10.1586/14779072.2013.815423.Peer-Reviewed Original ResearchConceptsStroke preventionAntithrombotic therapyAntithrombotic agentsNovel oral anticoagulation agentsAtrial fibrillation guidelinesOral anticoagulation agentsDrug-drug interactionsDirect antidoteAF patientsAnticoagulation monitoringAnticoagulation agentsAtrial fibrillationAbsolute riskAntithrombotic pharmacotherapyRelative riskLower riskStrong recommendationsPatientsThromboembolismPreventionRiskTherapyInherent risksAuthors' knowledgeAgents